Literature DB >> 35950390

[Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].

F Wang1, C P Qin1, Y Q DU1, S J Liu1, Q Li1, T Xu1.   

Abstract

OBJECTIVE: To determine the optimal cystoscopic frequency for intermediate-risk non-muscle invasive bladder cancer.
METHODS: Patients with intermediate-risk non-muscle invasive bladder cancer, who underwent transurethral resection of bladder tumor in Peking University People's Hospital from January 2001 to October 2019, were retrospectively analyzed. Their clinical, pathological and follow-up data were collected. In postoperative 2-year period, the patients were underwent cystoscopy every 3 to 6 months. Depending on recurrence and progression of the patients, we hypothesized three strategies of surveillance intensity in the first 2 years after surgery: model 1: 3-month intervals, model 2: 6-month intervals, and model 3: 12-month intervals. The differences in the numbers and time of delayed detection of recurrence and progression were compared among the three models.
RESULTS: A total of 185 patients were enrolled, including 144 males (77.8%) and 41 females (22.2%). The median age was 68 (59-76) years. There were 118 cases (63.8%) with single tumor and 67 cases (36.2%) with multiple tumor. Of the patients 179 (96.8%) had stage Ta and 6 (3.2%) had stage T1. There were 108 cases (58.4%) with high-grade disease and 77 cases (41.6%) with low-grade disease. During the follow-up period of the first 2 years, 52 patients (28.1%) had recurrence, 133 cases (71.9%) had no recurrence, 11 cases (5.9%) had progression and 174 cases (94.1%) had no progression. Compared with model 1, 29 (55.8%) delayed detection of recurrence in model 2 vs. 41 (78.8%) delayed detection of recurrence in model 3, and the difference was statistically significant (P=0.012). The median delayed time of detecting recurrence was 1.00 months in model 1, 1.99 months in model 2 and 4.19 months in model 3, respectively. There were statistically significant differences between mode 1 and model 3 (P=0.001), and between model 2 and model 3 (P=0.013). Compared with model 1, 5 (45.4%) delayed detection of progression in model 2 vs. 8 (72.7%) delayed detection of progression in model 3, and the difference was not statistically significant. The median delayed time of detecting progression was 1.00 month in model 1, 2.00 months in model 2 and 3.00 months in model 3, respectively. There was no statistically significant difference among them.
CONCLUSION: Although providing slightly slower detection of tumor recurrence and progression, compared with 3-month intervals of cystoscopy, 6-month intervals do not result in serious adverse outcomes and reduce cost and pain of the patients, which is feasible in intermediate-risk non-muscle invasive bladder cancer.

Entities:  

Keywords:  Bladder cancer; Cystoscopy; Follow-up; Surveillance intensity

Mesh:

Year:  2022        PMID: 35950390      PMCID: PMC9385523     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  18 in total

1.  Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort.

Authors:  Chad R Ritch; Maria C Velasquez; Deukwoo Kwon; Maria F Becerra; Nachiketh Soodana-Prakash; Venkatasai S Atluri; Katherine Almengo; Mahmoud Alameddine; Omer Kineish; Bruce R Kava; Sanoj Punnen; Dipen J Parekh; Mark L Gonzalgo
Journal:  J Urol       Date:  2019-10-14       Impact factor: 7.450

2.  Delay and survival in bladder cancer.

Authors:  D M A Wallace; R T Bryan; J A Dunn; G Begum; S Bathers
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

3.  Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.

Authors:  Abhishek Bhat; Deukwoo Kwon; Nachiketh Soodana-Prakash; Ali Mouzannar; Sanoj Punnen; Mark L Gonzalgo; Dipen J Parekh; Chad R Ritch
Journal:  J Urol       Date:  2021-02-22       Impact factor: 7.450

Review 4.  Bladder cancer.

Authors:  Ashish M Kamat; Noah M Hahn; Jason A Efstathiou; Seth P Lerner; Per-Uno Malmström; Woonyoung Choi; Charles C Guo; Yair Lotan; Wassim Kassouf
Journal:  Lancet       Date:  2016-06-23       Impact factor: 79.321

Review 5.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

Authors:  Bas W G van Rhijn; Maximilian Burger; Yair Lotan; Eduardo Solsona; Christian G Stief; Richard J Sylvester; J Alfred Witjes; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2009-06-26       Impact factor: 20.096

6.  Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.

Authors:  Yuki Kohada; Tetsutaro Hayashi; Ryan S Hsi; Kazuma Yukihiro; Kazuhiro Sentani; Keisuke Goto; Shogo Inoue; Shinya Ohara; Jun Teishima; Mitsuru Kajiwara; Takashi Nishisaka; Wataru Yasui; Peter C Black; Akio Matsubara
Journal:  BJU Int       Date:  2020-09-21       Impact factor: 5.588

7.  Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target.

Authors:  Darryl T Martin; Hongliang Shen; Jill M Steinbach-Rankins; Xi Zhu; Katelyn K Johnson; Jamil Syed; W Mark Saltzman; Robert M Weiss
Journal:  Mol Cancer Ther       Date:  2018-10-31       Impact factor: 6.261

Review 8.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Authors:  Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup
Journal:  Eur Urol       Date:  2019-08-20       Impact factor: 20.096

9.  Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies.

Authors:  Francesco Soria; David D'Andrea; Mohammad Abufaraj; Marco Moschini; Andrea Giordano; Kilian M Gust; Pierre I Karakiewicz; Marek Babjuk; Paolo Gontero; Shahrokh F Shariat
Journal:  Eur Urol Focus       Date:  2020-06-09

10.  Health-related quality of life after treatment for bladder cancer in England.

Authors:  Samantha J Mason; Amy Downing; Penny Wright; Luke Hounsome; Sarah E Bottomley; Jessica Corner; Mike Richards; James W Catto; Adam W Glaser
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.